1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with Scleroderma, Systemic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gruber, BL | 1 |
| Ioannidis, JP; Moutsopoulos, HM; Petrovas, CA; Tektonidou, MG; Vlachoyiannopoulos, PG | 1 |
| Jayson, MI; Klimiuk, PS; Price, JE | 1 |
1 review(s) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Scleroderma, Systemic
| Article | Year |
|---|---|
Mast cells: accessory cells which potentiate fibrosis.
Topics: Animals; Cytokines; Fibrosis; Histamine Release; Humans; Mast Cells; Platelet Activating Factor; Proteoglycans; Scleroderma, Systemic | 1995 |
2 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Scleroderma, Systemic
| Article | Year |
|---|---|
Clinical importance of antibodies against platelet activating factor in antiphospholipid syndrome manifestations.
Topics: Adult; Aged; Antibodies, Anticardiolipin; Antibody Specificity; Antiphospholipid Syndrome; beta 2-Glycoprotein I; Enzyme-Linked Immunosorbent Assay; Female; Glycoproteins; Humans; Immunoglobulin G; Immunoglobulin M; Male; Middle Aged; Odds Ratio; Phosphatidylcholines; Platelet Activating Factor; Scleroderma, Systemic; Seroepidemiologic Studies; Thrombosis | 2000 |
In vitro platelet aggregability studies: lack of evidence for platelet hyperactivity in systemic sclerosis.
Topics: Adenosine Diphosphate; Adult; Aged; Blood Coagulation Factors; Blood Platelets; Collagen; Female; Humans; In Vitro Techniques; Lactones; Middle Aged; Plant Extracts; Platelet Activating Factor; Platelet Aggregation; Scleroderma, Systemic | 1991 |